163 related articles for article (PubMed ID: 23871851)
21. The effects of strength training and raloxifene on bone health in aging ovariectomized rats.
Stringhetta-Garcia CT; Singulani MP; Santos LF; Louzada MJ; Nakamune AC; Chaves-Neto AH; Rossi AC; Ervolino E; Dornelles RC
Bone; 2016 Apr; 85():45-54. PubMed ID: 26812611
[TBL] [Abstract][Full Text] [Related]
22. Microstructural and compositional contributions towards the mechanical behavior of aging human bone measured by cyclic and impact reference point indentation.
Abraham AC; Agarwalla A; Yadavalli A; Liu JY; Tang SY
Bone; 2016 Jun; 87():37-43. PubMed ID: 27021150
[TBL] [Abstract][Full Text] [Related]
23. Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice.
Cano A; Dapía S; Noguera I; Pineda B; Hermenegildo C; del Val R; Caeiro JR; García-Pérez MA
Osteoporos Int; 2008 Jun; 19(6):793-800. PubMed ID: 17968609
[TBL] [Abstract][Full Text] [Related]
24. Effects of novel raloxifene analogs alone or in combination with mechanical loading in the Col1a2
Kohler R; Creecy A; Williams DR; Allen MR; Wallace JM
Bone; 2024 Feb; 179():116970. PubMed ID: 37977416
[TBL] [Abstract][Full Text] [Related]
25. Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.
Takeda S; Sakai S; Shiraishi A; Koike N; Mihara M; Endo K
Bone; 2013 Mar; 53(1):167-73. PubMed ID: 23232307
[TBL] [Abstract][Full Text] [Related]
26. Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Jee WS; Sato M
J Bone Miner Metab; 2005; 23 Suppl():62-8. PubMed ID: 15984416
[TBL] [Abstract][Full Text] [Related]
27. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
[TBL] [Abstract][Full Text] [Related]
28. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
29. Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis.
Ramalho-Ferreira G; Faverani LP; Grossi-Oliveira GA; Okamoto T; Okamoto R
J Biomed Opt; 2015 Mar; 20(3):038003. PubMed ID: 25813805
[TBL] [Abstract][Full Text] [Related]
30. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
Kendler DL; Palacios S; Cox DA; Stock J; Alam J; Dowsett SA; Zanchetta J
Osteoporos Int; 2012 Mar; 23(3):1091-101. PubMed ID: 21374068
[TBL] [Abstract][Full Text] [Related]
31. Finite element simulation of Reference Point Indentation on bone.
Idkaidek A; Agarwal V; Jasiuk I
J Mech Behav Biomed Mater; 2017 Jan; 65():574-583. PubMed ID: 27721174
[TBL] [Abstract][Full Text] [Related]
32. Characterization of damage mechanisms associated with reference point indentation in human bone.
Beutel BG; Kennedy OD
Bone; 2015 Jun; 75():1-7. PubMed ID: 25659950
[TBL] [Abstract][Full Text] [Related]
33. Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study.
Matheny JB; Slyfield CR; Tkachenko EV; Lin I; Ehlert KM; Tomlinson RE; Wilson DL; Hernandez CJ
Bone; 2013 Nov; 57(1):277-83. PubMed ID: 23988275
[TBL] [Abstract][Full Text] [Related]
34. Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.
Allen MR; Burr DB
Osteoporos Int; 2008 Jan; 19(1):95-9. PubMed ID: 17710353
[TBL] [Abstract][Full Text] [Related]
35. Combining raloxifene and mechanical loading improves bone composition and mechanical properties in a murine model of chronic kidney disease (CKD).
Surowiec RK; Reul ON; Chowdhury NN; Rai RK; Segvich D; Tomaschke AA; Damrath J; Jacobson AM; Allen MR; Wallace JM
Bone; 2024 Jun; 183():117089. PubMed ID: 38575047
[TBL] [Abstract][Full Text] [Related]
36. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
[TBL] [Abstract][Full Text] [Related]
37. Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats.
Lama A; Santoro A; Corrado B; Pirozzi C; Paciello O; Pagano TB; Russo S; Calignano A; Mattace Raso G; Meli R
PLoS One; 2017; 12(2):e0171276. PubMed ID: 28158228
[TBL] [Abstract][Full Text] [Related]
38. Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties.
Gallant MA; Brown DM; Hammond M; Wallace JM; Du J; Deymier-Black AC; Almer JD; Stock SR; Allen MR; Burr DB
Bone; 2014 Apr; 61():191-200. PubMed ID: 24468719
[TBL] [Abstract][Full Text] [Related]
39. Raloxifene prevents skeletal fragility in adult female Zucker Diabetic Sprague-Dawley rats.
Hill Gallant KM; Gallant MA; Brown DM; Sato AY; Williams JN; Burr DB
PLoS One; 2014; 9(9):e108262. PubMed ID: 25243714
[TBL] [Abstract][Full Text] [Related]
40. [Effects of SERMs on bone health. SERM and metabolic markers of bone].
Takami M; Shimada H
Clin Calcium; 2010 Mar; 20(3):365-71. PubMed ID: 20190366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
